The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
The company stated that it will work closely with the regulator to address the observations within the stipulated timeframe
ANDA approval for 100 mg and 150 mg capsules targeting idiopathic pulmonary fibrosis opens access to a $3.76 billion market in USA
Company to launch product after the expiry of semaglutide patent in India
_256_384.jpg)
Cipla has reported total income of Rs. 7,280.82 crore during the period ended December 31, 2025
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
This marks the first partnership between Pfizer and Cipla in India
Subscribe To Our Newsletter & Stay Updated
